Cargando…

IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines

The recent RESORCE trial showed that treatment with Regorafenib after Sorafenib failure provided a significant improvement in overall survival in HCC patients. Preclinical and clinical trial data showed that Regorafenib is a more potent drug than Sorafenib. In this study we aimed at improving Regora...

Descripción completa

Detalles Bibliográficos
Autores principales:	Refolo, Maria Grazia, D’Alessandro, Rosalba, Lippolis, Catia, Carella, Nicola, Cavallini, Aldo, Messa, Caterina, Carr, Brian Irving
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732742/ https://www.ncbi.nlm.nih.gov/pubmed/29262576 http://dx.doi.org/10.18632/oncotarget.21403

Ejemplares similares

Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells
por: Refolo, Maria Grazia, et al.
Publicado: (2018)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1
por: Lippolis, Catia, et al.
Publicado: (2015)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)

Inflammatory Mechanisms of HCC Development
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Platelet extracts induce growth, migration and invasion in human hepatocellular carcinoma in vitro
por: Carr, Brian I, et al.
Publicado: (2014)

The role of miRNA-133b and its target gene SIRT1 in FAP-derived desmoid tumor
por: Rotelli, Maria Teresa, et al.
Publicado: (2020)

Molecular mechanisms of synergistic action of Ramucirumab and Paclitaxel in Gastric Cancers cell lines
por: Refolo, Maria Grazia, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease: Focus on New Biomarkers and Lifestyle Interventions
por: Notarnicola, Maria, et al.
Publicado: (2021)

The Effects of Chronic Lifelong Activation of the AHR Pathway by Industrial Chemical Pollutants on Female Human Reproduction
por: Cavallini, Aldo, et al.
Publicado: (2016)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer
por: Yuan, Tao, et al.
Publicado: (2023)

Linsitinib and aspirin as the IGF1-R antagonists, inhibit regorafenib-resistant chemotherapy in colon cancer
por: Guo, Yu, et al.
Publicado: (2022)

Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations
por: Cavallini, Aldo, et al.
Publicado: (2017)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Regorafenib combined with sintilimab as second-line treatment for advanced HCC patient: a case report
por: Wan, Yanzhi, et al.
Publicado: (2023)

IGF2 and IGF1R mRNAs Are Detectable in Human Spermatozoa
por: Cannarella, Rossella, et al.
Publicado: (2020)

Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study
por: D’Alessandro, Rosalba, et al.
Publicado: (2022)

Corrigendum: Variations in circulating levels of angiopoietin-2 over time are predictive of ramucirumab–paclitaxel therapy outcome in advanced gastric cancer: results of prospective study
por: D’Alessandro, Rosalba, et al.
Publicado: (2023)

Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022)

Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
por: Daudigeos-Dubus, Estelle, et al.
Publicado: (2015)

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer
por: Schmieder, Roberta, et al.
Publicado: (2014)

Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer
por: Huynh, Hung, et al.
Publicado: (2015)

Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro
por: Dituri, Francesco, et al.
Publicado: (2020)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

GSTZ1‐1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone
por: Yang, Fan, et al.
Publicado: (2019)

HCC, diet and metabolic factors: Diet and HCC
por: Montella, Maurizio, et al.
Publicado: (2011)

VTIQ evaluates antitumor effects of NET-1 siRNA by UTMD in HCC xenograft models
por: Liang, Xitian, et al.
Publicado: (2018)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

SHP-1 is a target of regorafenib in colorectal cancer
por: Fan, Li-Ching, et al.
Publicado: (2014)

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
por: Breitenecker, Kristina, et al.
Publicado: (2023)

IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
por: Hussmann, Dianna, et al.
Publicado: (2017)

Polyunsaturated fatty acids reduce Fatty Acid Synthase and Hydroxy-Methyl-Glutaryl CoA-Reductase gene expression and promote apoptosis in HepG2 cell line
por: Notarnicola, Maria, et al.
Publicado: (2011)

Synergic effect of Eicosapentaenoic acid and Lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells
por: Notarnicola, Maria, et al.
Publicado: (2010)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
por: Hempel, Cornelius, et al.
Publicado: (2017)

Effect of Regorafenib on P2X7 Receptor Expression and Different Oncogenic Signaling Pathways in a Human Breast Cancer Cell Line: A Potential of New Insight of the Antitumor Effects of Regorafenib
por: Salahuddin, Muhammed M., et al.
Publicado: (2021)

Expression Levels of Three Key Genes CCNB1, CDC20, and CENPF in HCC Are Associated With Antitumor Immunity
por: Si, Tengfei, et al.
Publicado: (2021)

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib
por: Wang, Haochen, et al.
Publicado: (2022)

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Huang, Jingjun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_a40t5648ah5kf9vvv0cr27dbe5